6 completed, 3 recruiting, 2 withdrawn, 1 unknown. 6 Phase 2, 2 Not applicable, 2 Phase 3, 1 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 3, Recruiting 2, Withdrawn 1 |
| Not applicable | 2 | Unknown 1, Withdrawn 1 |
| Phase 3 | 2 | Completed 1, Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 4 | 1 | Completed 1 |
Follow Hematopoietic Stem Cell Mobilization: new trials by email Literature Review of Hematopoietic Stem Cell Mobilization trials Research Report on Hematopoietic Stem Cell Mobilization
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy Autologous Hematopoietic Stem Cell Transplantation, Best Practice, Biospecimen Collection - Anaplastic Large Cell Lymphoma, ALK-Negative, Follicular Helper T-Cell Lymphoma | Phase 3 | Recruiting | Eastern Cooperative Oncology Group | 294 | 2025-06-18 | 2026-09-14 |
| CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Granulocyte Colony-Stimulating Factor - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Recruiting | City of Hope Medical Center | 216 | 2024-07-12 | 2026-03-10 |
| Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma pembrolizumab, gemcitabine, vinorelbine - Hodgkin Lymphoma, Relapsed or Refractory Hodgkin Lymphoma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 257 | 2018-08-01 | 2026-09-24 |
| Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma Bortezomib, Lenalidomide, Dexamethasone - Multiple Myeloma | Phase 2 | Completed | Dana-Farber Cancer Institute | 46 | 2015-12-01 | 2026-01-13 |
| Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM Lenalidomide, Elotuzumab, Bortezomib - Multiple Myeloma | Phase 2 | Completed | Dana-Farber Cancer Institute | 40 | 2015-05-07 | 2024-10-01 |
| Pilot Study of Stem Cell Transplantation for Children and Young Adults With Refractory Crohn's Disease. Hematopoietic stem cell transplantation - Crohn's Disease | Not applicable | Withdrawn | TriStar Health | 2014-08-01 | 2018-02-07 | |
| Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma Autologous peripheral blood stem cell transplant, Lenalidomide, Dexamethasone - Multiple Myeloma | Phase 4 | Completed | Columbia University | 60 | 2012-09-01 | 2020-02-05 |
| RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma Autologous Hematopoietic Stem Cell Transplantation, Gamma-Secretase Inhibitor RO4929097, Hematopoietic Stem Cell Mobilization - DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2010-12-01 | 2017-09-28 | |
| Effects of Talocrural Joint Mobilizations in the Treatment of Subacute Lateral Ankle Sprains Mobilization therapy in addition to standard therapy, Sham intervention - Ankle Sprain | Not applicable | Unknown | University of Virginia | 60 | 2010-04-01 | 2011-05-30 |
| Safety Study of Parathyroid Hormone in Patients Needing Additional Stem Cell Mobilization. Stem cell mobilization - Lymphoma, Multiple Myeloma | Phase 1 | Completed | Massachusetts General Hospital | 12 | 2004-07-01 | 2007-04-24 |
| Stem Cell Mobilization to Treat Chest Pain and Shortness of Breath in Patients With Coronary Artery Disease Stem Cell Mobilization - Coronary Artery Disease | Phase 2 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 35 | 2002-08-01 | 2008-03-04 |
| Tandem Melphalan and Autolog. SCT in MM Patients 60 to 70 Years of Age With and Without Induction Chemotherapy Anthracycline/dexamethasone-based induction chemotherapy, Dexamethasone for control of symptoms, Tumor-reduction chemotherapy and stem cell mobilization - Multiple Myeloma | Phase 3 | Completed | WiSP Wissenschaftlicher Service Pharma GmbH | 549 | 2001-08-01 | 2014-11-11 |
Multiple Myeloma (6) · Hodgkin Disease (2) · Leukemia, Myeloid, Acute (2) · Ankle Injuries (1) · Arthritis (1) · Athletic Injuries (1) · Coronary Artery Disease (1) · Crohn Disease (1) · Heart Diseases (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Lymphoma (1) · Lymphoma, Large-Cell, Anaplastic (1) · Lymphoma, Non-Hodgkin (1) · Lymphoma, T-Cell (1)
Dana-Farber Cancer Institute (2) · City of Hope Medical Center (1) · Columbia University (1) · Eastern Cooperative Oncology Group (1) · Massachusetts General Hospital (1) · Memorial Sloan Kettering Cancer Center (1) · National Cancer Institute (NCI) (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · TriStar Health (1) · University of Virginia (1) · WiSP Wissenschaftlicher Service Pharma GmbH (1)
United States (10) · Mexico (1)
Alison Moskowitz, MD (1) · Christian Straka, Prof. Dr. (1) · Haydar Frangoul, MD (1) · Jacob Laubach (1) · Jacob P. Laubach, MD (1) · Karen Ballen, M.D. (1) · Mecide Gharibo (1) · Nabila N Bennani (1) · Suzanne Lentzsch, MD (1) · Terry Grindstaff, PhD, DPT (1) · Vaibhav Agrawal, MD (1)
PMID 27662018, PMID 35132679, PMID 41698326
P30CA033572 (1), P30CA072720 (1), R01CA266783 (1), U01CA132194 (1), U10CA180820 (1)